Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMar032015	Fate Therapeutics Expands and Strengthens Leadership Team SAN DIEGO, March 3, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that Wendy Levin, M.D., M.S. Read All »	View HTML Fate Therapeutics Expands and Strengthens Leadership Team 14.6 KB
Toggle SummaryMay112010	Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announces the appointment of six respected research leaders to the Company’s Scientific Advisory Board (SAB). The new SAB members bring deep experience and expertise in systems biology, epigenetics, gene regulation, expression Read All »	View HTML Fate Therapeutics Expands Scientific Advisory Board to Advance iPSC Technology and Stem Cell Modulator Pipeline 12 KB
Toggle SummaryApr082010	Fate Therapeutics Expands Stem Cell Modulator Pipeline with Acquisition of Verio Therapeutics San Diego, CA and Ottawa, Canada – Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Read All »	View HTML Fate Therapeutics Expands Stem Cell Modulator Pipeline with Acquisition of Verio Therapeutics 12.6 KB
Toggle SummaryDec132022	Fate Therapeutics Features Multiple Novel Approaches to Eliminate Conditioning Chemotherapy for Off-the-shelf, iPSC-derived Cell Therapies at 2022 ASH Annual Meeting Next-generation Engineering Strategies Designed to Resist Host Immune Cell Rejection Show Enhanced Functionality and Persistence of iPSC-derived Cells in Preclinical Allogeneic Models SAN DIEGO , Dec. 13, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. Read All »	View HTML
Toggle SummaryAug202013	Fate Therapeutics Files Registration Statement for Proposed Initial Public Offering San Diego, CA – Fate Therapeutics, Inc., a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to Read All »	View HTML Fate Therapeutics Files Registration Statement for Proposed Initial Public Offering 11.2 KB
Toggle SummaryJul012009	Fate Therapeutics Granted Exclusive License by The Regents of the University of California to Stem Cell Modulators for Osteo-Regeneration La Jolla, CA – Fate Therapeutics, Inc. announced today that it has acquired exclusive intellectual property rights covering small molecule compositions and methods for inducing bone formation from The Regents of the University of California. These proprietary osteogenic agents were developed Read All »	View HTML Fate Therapeutics Granted Exclusive License by The Regents of the University of California to Stem Cell Modulators for Osteo-Regeneration 10.6 KB
Toggle SummaryDec082014	Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood SAN DIEGO , Dec. 8, 2014 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, will present today an overview of the effects of using its nutrient-rich media (NRM) Read All »	View HTML Fate Therapeutics Highlights Effects of Nutrient-Rich Media on Ex Vivo Programmed CD34+ Cells Sourced From Umbilical Cord Blood 22.4 KB
Toggle SummaryDec102022	Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose Escalation Cohorts as Monotherapy and in Combination with Daratumumab Preclinical Data under Janssen Collaboration with FT555 GPRC5D-targeted Product Candidate Demonstrate Robust and Durable Read All »	View HTML
Toggle SummaryDec132021	Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL 6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million FT516 Cells per Dose 3 of 8 Patients Previously Treated with Autologous CAR T-cell Therapy Achieve Read All »	View HTML
Toggle SummaryJun042021	Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting 8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response 6 of 11 Patients Achieved Complete Response, including 2 Patients Previously Treated with Autologous CD19 CAR T-cell Therapy Favorable FT516 Safety Profile Was Observed; No FT516-related Serious Adverse Events or Read All »	View HTML

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.